Researchers dig into patient histories to uncover clues about macrophage activation syndrome
NCT ID NCT06992505
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study reviewed the medical charts of 32 people with Still's disease who developed a serious complication called macrophage activation syndrome (MAS). The goal was to learn more about their symptoms, how long it took for lab values to return to normal, and what treatments were used. No new drug or intervention was tested; instead, researchers gathered information to better understand the condition and its management.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
32 people
The number who actually took part.
- Started
-
Jun 2025
- Finished
-
Nov 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population will include patients with Still's disease who were diagnosed with MAS that was refractory to GC treatment.
- Ages
-
6 months to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age \>6 months and ≤80 years at the beginning of the index MAS episode. * Diagnosis of Still's disease (sJIA or AOSD diagnosis). * Diagnosis of MAS according to treating physician in the medical record. * Patients who have received at least 3 consecutive days of GC after diagnosis of MAS and/or are judged by the Investigator to be refractory to GC due to clinical worsening of patient's condition. * The onset of the index MAS episode occurred between 01 January 2012 and 30 September 2022. * According to local regulations, waivers of consent will be sought for study participants from the appropriate regulatory authorities and/or the independent ethics committee (IEC)/institutional review board (IRB). o For patients not covered by waivers of consent, signed, and dated informed consent provided by the patient, or the patient's legally authorized representative(s) for patients under the legal age (with patient assent, as applicable) or who have died, should be obtained before any study-related activities are undertaken. Exclusion Criteria: * A diagnosis of primary HLH prior to the beginning of the index MAS episode. * Confirmed malignancy prior to the beginning of the index MAS episode. * Patient treated with any investigational product as a part of clinical trial during the index MAS episode.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Macrophage activation syndrome (MAS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico
Milan, 20122, Italy
-
Ospedale Pediatrico Bambin Gesù
Rome, 00165, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immune clues in the blood may foretell heart trouble
- Pandemic stress hits hard for arthritis patients
- New drug combo aims to tame rare inflammatory disease
- 5,000 patients to help unlock secrets of inflammatory heart disease
- New study tracks ilaris use in rare inflammatory diseases across europe
- New study aims to uncover hidden danger in kawasaki disease